These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 18593723)

  • 21. Steady-state pharmacokinetic comparison of generic and branded formulations of stavudine, lamivudine and nevirapine in HIV-infected Ugandan adults.
    Byakika-Kibwika P; Lamorde M; Kalemeera F; D'Avolio A; Mauro S; Di Perri G; Ryan M; Mayanja-Kizza H; Khoo S; Back D; Boffito M; Merry C
    J Antimicrob Chemother; 2008 Nov; 62(5):1113-7. PubMed ID: 18641036
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pharmacokinetics of generic and trade formulations of lamivudine, stavudine and nevirapine in HIV-infected Malawian children.
    Corbett AH; Hosseinipour MC; Nyirenda J; Kanyama C; Rezk NL; Mkupani P; Sichali D; Tien H; Kashuba AD; Mwansambo C; Weigel R; Kazembe P
    Antivir Ther; 2010; 15(1):83-90. PubMed ID: 20167994
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pharmacokinetics of nevirapine in HIV-infected infants weighing 3 kg to less than 6 kg taking paediatric fixed dose combination tablets.
    Fillekes Q; Mulenga V; Kabamba D; Kankasa C; Thomason MJ; Cook A; Ferrier A; Chintu C; Walker AS; Gibb DM; Burger DM
    AIDS; 2012 Sep; 26(14):1795-800. PubMed ID: 22739394
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Factors influencing plasma nevirapine levels: a study in HIV-infected children on generic antiretroviral treatment in India.
    Swaminathan S; Ramachandran G; Agibothu Kupparam HK; Mahalingam V; Soundararajan L; Perumal Kannabiran B; Navaneethapandian PG; Shah I; Karunaianandham R; Sikhamani R
    J Antimicrob Chemother; 2011 Jun; 66(6):1354-9. PubMed ID: 21393201
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Nevirapine pharmacokinetics when initiated at 200 mg or 400 mg daily in HIV-1 and tuberculosis co-infected Ugandan adults on rifampicin.
    Lamorde M; Byakika-Kibwika P; Okaba-Kayom V; Ryan M; Coakley P; Boffito M; Namakula R; Kalemeera F; Colebunders R; Back D; Khoo S; Merry C
    J Antimicrob Chemother; 2011 Jan; 66(1):180-3. PubMed ID: 21047828
    [TBL] [Abstract][Full Text] [Related]  

  • 26. No relationship between high nevirapine plasma concentration and hepatotoxicity in HIV-1-infected patients naive of antiretroviral treatment or switched from protease inhibitors.
    Dailly E; Billaud E; Reliquet V; Breurec S; Perré P; Léautez S; Jolliet P; Bourin M; Raffi F
    Eur J Clin Pharmacol; 2004 Jul; 60(5):343-8. PubMed ID: 15156302
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparison of nevirapine plasma concentrations between lead-in and steady-state periods in Chinese HIV-infected patients.
    Kou H; Du X; Li Y; Xie J; Qiu Z; Ye M; Fu Q; Han Y; Zhu Z; Li T
    PLoS One; 2013; 8(1):e52950. PubMed ID: 23359265
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Population pharmacokinetics of efavirenz in an unselected cohort of HIV-1-infected individuals.
    Kappelhoff BS; Huitema AD; Yalvaç Z; Prins JM; Mulder JW; Meenhorst PL; Beijnen JH
    Clin Pharmacokinet; 2005; 44(8):849-61. PubMed ID: 16029069
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The steady-state pharmacokinetics of efavirenz and nevirapine when used in combination in human immunodeficiency virus type 1-infected persons.
    Veldkamp AI; Harris M; Montaner JS; Moyle G; Gazzard B; Youle M; Johnson M; Kwakkelstein MO; Carlier H; van Leeuwen R; Beijnen JH; Lange JM; Reiss P; Hoetelmans RM
    J Infect Dis; 2001 Jul; 184(1):37-42. PubMed ID: 11398107
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Race is not associated with nevirapine pharmacokinetics.
    de Maat MM; Nellen JF; Huitema AD; Wit FW; Mulder JW; Prins JM; Beijnen JH
    Ther Drug Monit; 2004 Aug; 26(4):456-8. PubMed ID: 15257078
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Once-daily dosing of saquinavir and low-dose ritonavir in HIV-1-infected individuals: a pharmacokinetic pilot study.
    van Heeswijk RP; Veldkamp AI; Mulder JW; Meenhorst PL; Lange JM; Beijnen JH; Hoetelmans RM
    AIDS; 2000 Jun; 14(9):F103-10. PubMed ID: 10894270
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effect of
    Monera-Penduka TG; Maponga CC; Wolfe AR; Wiesner L; Morse GD; Nhachi CF
    AIDS Res Ther; 2017; 14():12. PubMed ID: 28293270
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Steady-state pharmacokinetics of tenofovir disoproxil fumarate in human immunodeficiency virus-infected Chinese patients.
    Du X; Kou H; Fu Q; Li Y; Zhu Z; Li T
    Expert Rev Clin Pharmacol; 2017 Jul; 10(7):783-788. PubMed ID: 28480762
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Are adverse events of nevirapine and efavirenz related to plasma concentrations?
    Kappelhoff BS; van Leth F; Robinson PA; MacGregor TR; Baraldi E; Montella F; Uip DE; Thompson MA; Russell DB; Lange JM; Beijnen JH; Huitema AD;
    Antivir Ther; 2005; 10(4):489-98. PubMed ID: 16038474
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Population pharmacokinetic and pharmacogenetic analysis of nevirapine in hypersensitive and tolerant HIV-infected patients from Malawi.
    Dickinson L; Chaponda M; Carr DF; van Oosterhout JJ; Kumwenda J; Lalloo DG; Pirmohamed M; Heyderman RS; Khoo SH
    Antimicrob Agents Chemother; 2014; 58(2):706-12. PubMed ID: 24217698
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effect of diurnal variation, CYP2B6 genotype and age on the pharmacokinetics of nevirapine in African children.
    Bienczak A; Cook A; Wiesner L; Mulenga V; Kityo C; Kekitiinwa A; Walker AS; Owen A; Gibb DM; Burger D; McIlleron H; Denti P
    J Antimicrob Chemother; 2017 Jan; 72(1):190-199. PubMed ID: 27707991
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Nevirapine Pharmacokinetics and Safety in Neonates Receiving Combination Antiretroviral Therapy for Prevention of Vertical HIV Transmission.
    Lau E; Brophy J; Samson L; Kakkar F; Campbell DM; Yudin MH; Murphy K; Seto W; Colantonio D; Read SE; Bitnun A
    J Acquir Immune Defic Syndr; 2017 Apr; 74(5):493-498. PubMed ID: 28114187
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Simultaneous pharmacogenetics-based population pharmacokinetic analysis of darunavir and ritonavir in HIV-infected patients.
    Moltó J; Xinarianos G; Miranda C; Pushpakom S; Cedeño S; Clotet B; Owen A; Valle M
    Clin Pharmacokinet; 2013 Jul; 52(7):543-53. PubMed ID: 23494984
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Impact of adherence and anthropometric characteristics on nevirapine pharmacokinetics and exposure among HIV-infected Kenyan children.
    Vreeman RC; Nyandiko WM; Liechty EA; Busakhala N; Bartelink IH; Savic RM; Scanlon ML; Ayaya SO; Blaschke TF
    J Acquir Immune Defic Syndr; 2014 Nov; 67(3):277-86. PubMed ID: 25140906
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Once-daily nevirapine dosing: a pharmacokinetics, efficacy and safety review.
    Cooper CL; van Heeswijk RP
    HIV Med; 2007 Jan; 8(1):1-7. PubMed ID: 17305925
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.